Does Humana Cover Prometrium?

Humana Formulary Placement for Prometrium

Most Humana commercial and marketplace plans include generic micronized progesterone on their formularies, though the exact tier placement depends on your specific plan document. Brand-name Prometrium is less consistently covered and may require a formulary exception request.

Commercial Plan Tiers

On Humana's commercial formularies, generic micronized progesterone typically sits at Tier 2 (preferred brand) with copays ranging from $20 to $40 for a 30-day supply. Brand-name Prometrium, when listed, usually falls on Tier 3 (non-preferred brand) with copays between $40 and $75. Some high-deductible plans apply full cost until the deductible is met, meaning you could pay closer to the $180 list price for brand or $45 cash price for generic in early months of the plan year.

Humana updates its formulary at least once per calendar year, and mid-year changes can shift tier placement. Always verify your plan's current formulary through Humana's online drug lookup tool or by calling the member services number on your insurance card.

Medicare Advantage Plans

Humana Medicare Advantage (MA) plan coverage for Prometrium is more variable. CMS requires Part D plans to cover at least two drugs in each therapeutic category, and micronized progesterone competes with medroxyprogesterone acetate (MPA) and norethindrone acetate in the progestin class. Some MA plans exclude brand-name Prometrium entirely while covering generic micronized progesterone. Others impose quantity limits of 30 capsules per fill.

The Endocrine Society's 2022 menopause hormone therapy guidelines recommend micronized progesterone over synthetic progestins for most women based on a more favorable cardiovascular and breast-safety profile. This recommendation can support a formulary exception request if your plan prefers MPA.

Prior Authorization Requirements

Prior authorization (PA) is the most common barrier Humana members face when filling a Prometrium prescription. The process requires your prescribing clinician to submit clinical documentation justifying the medication before the pharmacy can dispense it.

What Triggers a PA

Humana may require prior authorization for Prometrium or its generic in several scenarios. Brand-name requests when a generic is available will almost always trigger PA. Doses outside the standard 200 mg daily for 12 days per cycle (the FDA-approved regimen) can also flag a review. Continuous daily dosing at 100 mg, while supported by clinical evidence for endometrial protection, may not match the label language and could require additional documentation.

Approval Criteria

Humana's PA criteria generally require documentation of the following: a confirmed diagnosis of menopause or perimenopause, concurrent use of estrogen therapy (oral, transdermal, or vaginal at systemic doses), and an intact uterus. The PEPI trial (Postmenopausal Estrogen/Progestin Interventions, N=875) demonstrated that micronized progesterone 200 mg cyclically for 12 days per month effectively prevented endometrial hyperplasia while producing significantly less HDL-lowering effect than MPA 1. This trial remains a cornerstone of clinical justification for micronized progesterone over synthetic alternatives.

Timeline and Denial Rates

Standard PA decisions from Humana arrive within 72 hours for non-urgent requests and 24 hours for urgent requests. For Medicare Advantage members, CMS mandates a 72-hour standard timeline and 24-hour expedited timeline. Denial rates for Prometrium PA requests on Humana MA plans tend to be moderate to high, particularly when the plan formulary already includes MPA as a preferred alternative.

Dr. Karen Carlson, an OB-GYN and menopause specialist at Massachusetts General Hospital, has noted: "Many insurers treat progestins as interchangeable, but the clinical data clearly show that micronized progesterone and medroxyprogesterone have different metabolic and breast-tissue effects. A prior authorization denial based solely on therapeutic equivalence ignores the evidence from PEPI and subsequent observational studies."

Step Therapy: Will Humana Make You Try Another Drug First?

Some Humana plans impose step therapy (also called "fail first") protocols that require you to try and fail on a less expensive progestin before they will approve Prometrium or its generic. This is more common on Medicare Advantage and some marketplace (ACA) plans than on employer-sponsored commercial plans.

Typical Step Therapy Sequence

The most common step therapy requirement is a trial of medroxyprogesterone acetate (Provera), which costs as little as $4 to $10 per month at most pharmacies. Humana may require 30 to 90 days of documented MPA use with evidence of intolerance or adverse effects before approving micronized progesterone.

How to Bypass Step Therapy

Your prescriber can request a step therapy exception if clinical reasons make MPA inappropriate for you. Valid medical reasons include a history of MPA side effects (breast tenderness, mood changes, bloating), a personal or family history of breast cancer where micronized progesterone's potentially lower breast-cancer risk profile matters, or metabolic concerns such as dyslipidemia where MPA's HDL-lowering effect is clinically relevant.

The Women's Health Initiative observational arm and the French E3N cohort study (N=80,377) found that estrogen combined with micronized progesterone was associated with no significant increase in breast cancer risk (RR 1.00, 95% CI 0.83 to 1.22) over a mean follow-up of 8.1 years, while estrogen plus synthetic progestins showed a statistically significant increase 2. These data provide strong clinical rationale for a step therapy override.

How to Appeal a Humana Prometrium Denial

A denial from Humana is not the final word. Federal and state law guarantee your right to appeal, and the process differs depending on whether you have a commercial plan or Medicare Advantage coverage.

Internal Appeal Process

For both commercial and MA plans, the first step is filing an internal appeal with Humana. You or your prescriber must submit the appeal within 60 days of the denial notice (180 days for MA plans). Include supporting clinical documentation: your diagnosis, why micronized progesterone is medically necessary over alternatives, relevant lab work (such as lipid panels showing dyslipidemia that MPA would worsen), and citations to clinical evidence.

Humana must respond to a standard internal appeal within 30 days for commercial plans. MA plan members receive a decision within 7 days for standard appeals or 72 hours for expedited appeals when delay could seriously jeopardize health.

External Review and MAXIMUS

If Humana upholds the denial after internal appeal, commercial plan members can request an independent external review through their state's insurance department. Medicare Advantage members have a distinct pathway: the case goes to MAXIMUS, the CMS-contracted Independent Review Entity (IRE). MAXIMUS reviews the clinical evidence independently of Humana.

The external review overturn rate for Part D medication denials has historically been meaningful. Successful appeals typically include a detailed letter of medical necessity from the prescriber, peer-reviewed citations (particularly PEPI 1 and the E3N data 2), and documentation of adverse reactions to step therapy alternatives.

Tips for a Stronger Appeal

Write the appeal letter on practice letterhead with the prescriber's NPI number. Reference Humana's specific denial reason code and address it directly. Attach copies of relevant studies rather than simply naming them. If the patient experienced side effects on MPA, include dated chart notes documenting those effects. A well-documented appeal submitted promptly has a substantially higher success rate than a generic "please reconsider" letter.

Cost Breakdown: Brand vs. Generic vs. Cash Pay

Understanding pricing helps you manage coverage gaps and make informed decisions if Humana denies coverage entirely.

Brand-Name Prometrium

The manufacturer list price for brand-name Prometrium runs approximately $180 per month for a 30-day supply of 200 mg capsules taken cyclically (12 days per month). With Humana Tier 3 coverage, your out-of-pocket cost typically falls between $40 and $75. Without insurance, the brand price rarely makes financial sense given the availability of generics.

Generic Micronized Progesterone

Generic versions of micronized progesterone (manufactured by Teva, Sun Pharma, and others) average approximately $45 per month at cash-pay pricing. With Humana Tier 2 coverage, expect copays of $15 to $35. Several pharmacy discount programs bring the cash-pay price to $15 to $25 per month, making it affordable even without insurance.

Manufacturer Savings Cards

Prometrium's manufacturer (AbbVie, following the Allergan acquisition) has periodically offered copay assistance cards for commercially insured patients. These cards typically cannot be combined with Medicare, Medicaid, or other government-funded insurance per federal anti-kickback statutes. If you carry Humana commercial insurance and your copay exceeds $35, check with your pharmacist about current manufacturer offers. For Humana MA members, savings cards are not usable 3.

Clinical Context: Why Prometrium Specifically?

Insurance formulary decisions often treat progestins as interchangeable, but the clinical evidence distinguishes micronized progesterone from synthetic progestins in several important ways.

Endometrial Protection

The PEPI trial (N=875) randomized postmenopausal women to five arms: placebo, conjugated equine estrogen (CEE) alone, CEE plus MPA cyclically, CEE plus MPA continuously, and CEE plus micronized progesterone cyclically. After 3 years, all progestin-containing regimens effectively prevented the endometrial hyperplasia seen in the estrogen-only arm (incidence 0% to 1% vs. 34% with CEE alone). Micronized progesterone matched MPA for endometrial safety.

Lipid Effects

The same trial showed that micronized progesterone preserved more of estrogen's beneficial effect on HDL cholesterol than MPA did. Women on CEE plus micronized progesterone had a mean HDL increase of 4.1 mg/dL, while those on CEE plus continuous MPA saw HDL rise only 1.2 mg/dL 1. For women with baseline dyslipidemia or cardiovascular risk factors, this difference carries clinical weight.

Breast Cancer Risk Profile

The E3N cohort study (N=80,377, mean follow-up 8.1 years) found no significant increase in breast cancer risk with estrogen plus micronized progesterone (RR 1.00), compared with a significant increase with estrogen plus synthetic progestins (RR 1.69) 2. The North American Menopause Society's 2022 position statement acknowledges this differential risk profile, though it stops short of recommending one progestin over another for all women. This data matters for appeal documentation, especially for women with elevated breast cancer risk.

Sleep and Tolerability

Micronized progesterone has mild sedative properties related to its allopregnanolone metabolite, a GABA-A receptor modulator. This can benefit postmenopausal women with concurrent sleep complaints. Taking the capsule at bedtime reduces daytime drowsiness while leveraging this effect 4. Synthetic progestins do not share this neurosteroid activity.

Practical Steps to Get Prometrium Covered by Humana

If you are starting hormone therapy and your clinician recommends micronized progesterone, a structured approach reduces delays and denials.

Before Your Pharmacy Visit

Ask your prescriber to write the prescription for generic micronized progesterone rather than brand-name Prometrium. This avoids the automatic brand-vs.-generic PA trigger on most Humana plans. Confirm with your prescriber's office that they have your Humana member ID and group number ready for any PA submissions.

At the Pharmacy

If the pharmacist reports a PA requirement, ask them to initiate a "pharmacy-initiated PA" (also called a coverage determination request) electronically through CoverMyMeds or a similar platform. Many pharmacies can start this process within minutes. Request a small cash-pay fill (7 to 14 days) at the generic price to avoid a gap in therapy while the PA processes.

If Denied

Do not accept the denial as permanent. Request the denial in writing, noting the specific reason code. Contact your prescriber's office the same day and ask them to file an expedited appeal if you have already started estrogen therapy, since unprotected estrogen exposure in a woman with an intact uterus raises endometrial hyperplasia risk. The clinical urgency of avoiding unopposed estrogen qualifies most cases for expedited review.

Your prescriber should attach the PEPI trial data 1 and the E3N breast cancer findings 2 to the appeal, along with any patient-specific factors (lipid panel, MPA intolerance history, breast cancer family history) that make micronized progesterone the preferred agent.